As the ASX 200 hovers just above the 9,000-point mark, traders are cautiously navigating market conditions influenced by global events and domestic earnings reports. In this environment of uncertainty, growth companies with significant insider ownership can offer a unique perspective on potential stability and confidence within their own ranks.

Top 10 Growth Companies With High Insider Ownership In Australia

Name Insider Ownership Earnings Growth Newfield Resources (ASX:NWF) 31.5% 72.1% IperionX (ASX:IPX) 18.7% 59.1% Image Resources (ASX:IMA) 22.3% 79.8% Gratifii (ASX:GTI) 17.8% 114.0% Findi (ASX:FND) 33.6% 91.2% Fenix Resources (ASX:FEX) 21.1% 54.7% Echo IQ (ASX:EIQ) 18% 51.4% Cyclopharm (ASX:CYC) 11.3% 97.8% BlinkLab (ASX:BB1) 39.8% 52.7% Acrux (ASX:ACR) 15.5% 106.9%

Click here to see the full list of 97 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

Beetaloo Energy Australia

Simply Wall St Growth Rating: ★★★★★☆

Overview: Beetaloo Energy Australia Limited, along with its subsidiaries, is involved in the production and sale of oil and natural gas in Australia, with a market capitalization of A$395.04 million.

Operations: The company generates revenue through the production and sale of oil and natural gas within Australia.

Insider Ownership: 22.6%

Beetaloo Energy Australia demonstrates significant insider confidence, with substantial insider buying over the past three months and no major selling. The company is poised for strong growth, with revenue expected to increase by 80.2% annually, outpacing market averages. However, recent shareholder dilution may concern some investors. The company's share price has been volatile recently, and it remains a small player in terms of revenue generation. Recent amendments to its constitution reflect strategic changes as it becomes Beetaloo Energy Group Limited.

Get an in-depth perspective on Beetaloo Energy Australia's performance by reading our analyst estimates report here. Our valuation report unveils the possibility Beetaloo Energy Australia's shares may be trading at a premium.ASX:BTL Earnings and Revenue Growth as at Aug 2025

PWR Holdings

Simply Wall St Growth Rating: ★★★★★☆

Overview: PWR Holdings Limited specializes in the design, production, and sale of cooling products and solutions across various international markets, with a market cap of A$779.37 million.

Operations: The company's revenue segments include A$42.33 million from PWR C&R and A$101.83 million from PWR Performance Products.

Insider Ownership: 13.3%

PWR Holdings shows potential as a growth company with high insider ownership, despite recent financial challenges. Its earnings are projected to grow significantly at 27.4% annually, outpacing the broader Australian market. However, revenue growth is slower at 14.3%, and net income has decreased from A$24.81 million to A$9.77 million year-on-year amid executive transitions, including founder Kees Weel's phased return and upcoming leadership changes following the AGM in October 2025.

Story Continues

Click to explore a detailed breakdown of our findings in PWR Holdings' earnings growth report. Upon reviewing our latest valuation report, PWR Holdings' share price might be too optimistic.ASX:PWH Ownership Breakdown as at Aug 2025

Telix Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★☆

Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals, with a market cap of A$6.20 billion.

Operations: The company's revenue segments include Therapeutics at $7.29 million, Precision Medicine at $575.13 million, and Manufacturing Solutions at $81.81 million.

Insider Ownership: 14.9%

Telix Pharmaceuticals demonstrates growth potential with high insider ownership, despite recent financial setbacks. The company's earnings are forecasted to grow significantly at 44.1% annually, surpassing the Australian market average. However, profit margins have declined from 7.6% to 1.6%, and it reported a net loss of US$2.29 million for H1 2025 despite revenue growth to US$390.36 million from US$239.61 million year-on-year, indicating operational challenges amid rapid expansion efforts and product developments like Gozellix®.

Take a closer look at Telix Pharmaceuticals' potential here in our earnings growth report. In light of our recent valuation report, it seems possible that Telix Pharmaceuticals is trading behind its estimated value.ASX:TLX Ownership Breakdown as at Aug 2025

Make It Happen

Reveal the 97 hidden gems among our Fast Growing ASX Companies With High Insider Ownership screener with a single click here. Interested In Other Possibilities? The end of cancer? These 26 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ASX:BTL ASX:PWH and ASX:TLX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments